MOHSIN SYED: Open Payments
NPI 1437291689 · NEW HARTFORD, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$924 in 55 payments from 14 companies in 2025. Trend: 2023 $1,409 · 2024 $1,404 · 2025 $924
Food & beverage: $924
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $259 |
| Amgen Inc. | 12 | $159 |
| Gilead Sciences, Inc. | 4 | $87 |
| Braeburn Inc. | 4 | $77 |
| GlaxoSmithKline, LLC. | 4 | $72 |
| Novo Nordisk Inc | 3 | $64 |
| Lilly USA, LLC | 3 | $50 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
Products named: VRAYLAR, OTEZLA, BRIXADI, REPATHA, QULIPTA, SHINGRIX, Wegovy, Kerendia.
Industry payments across NY — which companies pay providers there.
